All In Biotech

Drug Trial Radar · NCT02799602

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,306 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,306

Actual

Start

Nov 30, 2016

Primary completion

Oct 25, 2021

Study completion Apr 11, 2023

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Orion Corporation, Orion Pharma
First posted
Jun 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.

Conditions

  • Metastatic Hormone-sensitive Prostate Cancer

Interventions

  • BAY1841788 / darolutamide (ODM-201)Drug

    600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel

  • Standard ADT (androgen deprivation therapy)Drug

    As prescribed by the treating physician.

  • DocetaxelDrug

    As prescribed by the treating physician.

  • PlaceboDrug

    Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OS From Date of Randomization Until Death From Any Cause - Number of EventsTime frame: From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)
  2. OS From Date of Randomization Until Death From Any Cause - MonthTime frame: From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)

Locations

322 sites in 23 countries. Site status is shown where the registry gives one.

  • Site not named

    Chandler, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Beverly Hills, California

  • Site not named

    Duarte, California

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Boca Raton, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Louisville, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Towson, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Billings, Montana

  • Site not named

    Omaha, Nebraska

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Camden, New Jersey

  • Site not named

    Englewood, New Jersey

  • Site not named

    Hackensack, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Poughkeepsie, New York

  • Site not named

    Rochester, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Concord, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Gahanna, Ohio

Showing 40 of 322 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.